OTCMKTS:APLIF Appili Therapeutics Q1 2026 Earnings Report $0.0066 0.00 (-29.79%) As of 09/29/2026 03:06 PM Eastern ProfileEarnings History Appili Therapeutics EPS ResultsActual EPS-$0.01Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAppili Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAppili Therapeutics Announcement DetailsQuarterQ1 2026Date8/14/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Appili Therapeutics Earnings HeadlinesAppili Therapeutics to Delist from TSX and Move Listing to NEXSeptember 29 at 9:11 AM | tipranks.comAppili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 ProgramJuly 3, 2026 | financialpost.comFA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the country entirely - as concerns grow about the next phase of the AI market. One AI insider says investors should reassess their positions before September 30, pointing to a critical shift ahead for tech and AI-related stocks. | TradeSmith (Ad)Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 ProgramJuly 3, 2026 | globenewswire.comAppili Therapeutics Reports Fiscal Year 2026 Financial and Operational ResultsJune 26, 2026 | financialpost.comFAppili Therapeutics Reports Fiscal Year 2026 Financial and Operational ResultsJune 26, 2026 | globenewswire.comSee More Appili Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Appili Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Appili Therapeutics and other key companies, straight to your email. Email Address About Appili TherapeuticsAppili Therapeutics (OTCMKTS:APLIF) is a Canadian biopharmaceutical company focused on developing therapies and vaccines for infectious diseases and other conditions with significant unmet medical needs. The company has emphasized programs addressing bacterial and fungal infections, including drug-resistant pathogens and diseases that may pose risks to public health. Appili’s development portfolio has included ATI-1701, a live-attenuated vaccine candidate intended to protect against tularemia, and ATI-2307, an investigational antifungal agent being studied for serious fungal infections. The company has also pursued additional anti-infective programs and commercialization opportunities through licensing and strategic partnerships. Appili was founded in 2015 and is based in Halifax, Nova Scotia. Its activities have included collaborations with government agencies, research organizations and commercial partners in North America and other international markets, reflecting the global need for treatments targeting infectious diseases. The company’s shares have traded under the symbol APLI in Canada and APLIF on the OTC market.View Appili Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles CarMax Just Gave Investors a Better Reason to Believe in the TurnaroundBernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
